- Home
- CBUS vs IFRX Comparison
CBUS vs IFRX Comparison
Compare CBUS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBUS
- IFRX
- Stock Information
- Founded
- CBUS 2010
- IFRX 2007
- Country
- CBUS United States
- IFRX Germany
- Employees
- CBUS N/A
- IFRX 74
- Industry
- CBUS Agricultural Chemicals
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- CBUS Industrials
- IFRX Health Care
- Exchange
- CBUS Nasdaq
- IFRX Nasdaq
- Market Cap
- CBUS 65.3M
- IFRX 56.4M
- IPO Year
- CBUS 2017
- IFRX 2017
- Fundamental
- Price
- CBUS $1.55
- IFRX $0.80
- Analyst Decision
- CBUS Strong Buy
- IFRX Strong Buy
- Analyst Count
- CBUS 3
- IFRX 4
- Target Price
- CBUS $22.00
- IFRX $7.75
- AVG Volume (30 Days)
- CBUS 927.1K
- IFRX 282.5K
- Earning Date
- CBUS 08-07-2025
- IFRX 08-07-2025
- Dividend Yield
- CBUS N/A
- IFRX N/A
- EPS Growth
- CBUS N/A
- IFRX N/A
- EPS
- CBUS N/A
- IFRX N/A
- Revenue
- CBUS $4,751,000.00
- IFRX $140,242.00
- Revenue This Year
- CBUS $32.97
- IFRX N/A
- Revenue Next Year
- CBUS $66.40
- IFRX $6,309.47
- P/E Ratio
- CBUS N/A
- IFRX N/A
- Revenue Growth
- CBUS 104.78
- IFRX 30.90
- 52 Week Low
- CBUS $1.38
- IFRX $0.71
- 52 Week High
- CBUS $10.77
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- CBUS 42.57
- IFRX 37.46
- Support Level
- CBUS $1.40
- IFRX $0.78
- Resistance Level
- CBUS $1.67
- IFRX $0.83
- Average True Range (ATR)
- CBUS 0.14
- IFRX 0.04
- MACD
- CBUS 0.02
- IFRX 0.03
- Stochastic Oscillator
- CBUS 62.07
- IFRX 52.40
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.